COVID-19 With Convalescent Plasma

NCT04616976 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2020-11-05

No results posted yet for this study

Summary

To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.

Conditions

  • COVID-19 Convalescent Plasma Treatment

Interventions

BIOLOGICAL

convalescent plasma

convalescent plasma was get from the patients who recovery from COVID-19

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-02-29
Completion
2020-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616976 on ClinicalTrials.gov